Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00747539 · ClinicalTrials.gov registry record
Brain Deficits in HIV/HCV Coinfected People Before and After Anti-HCV Therapy
A clinical trial of HIV and Hepatitis C, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- 330
- Enrollment target
- 4
- Study locations
NCT00747539 is a study of HIV and Hepatitis C that has completed, run by University of California, Los Angeles. The registered enrollment target is 330 participants, below the 439-participant average among 303 other HIV trials with a reported enrollment target (25% lower). The trial reports 4 study locations across 1 state.
The verdict
NCT00747539, a study of HIV and Hepatitis C, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- 330 participants
- Enrollment target
- 4
- Study locations
Study Summary
This study will evaluate the impact of standard hepatitis C virus treatment on brain deficits in people who are infected with both HIV and the hepatitis C virus.
Conditions Studied
Interventions
- DRUG Pegylated interferon alfa and ribavirin (PEG-IFN/RBV)
Study Locations (4)
California
- Kaiser Permanente Infectious Diseases, Antelope Valley - Lancaster
- University of California, Los Angeles, School of Medicine - Los Angeles
- AIDS Healthcare Foundation - Los Angeles
- Veterans Administration Greater Los Angeles Healthcare System - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 330 participants |
| Start Date | 2008-07 |
| Est. Completion | 2015-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00747539
The ClinicalTrials.gov registry entry for NCT00747539 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 330 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 439-participant average among 303 other HIV trials with a reported enrollment target (25% lower). The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with HIV appearing as the primary indexed condition, and to 1 intervention - of which Pegylated interferon alfa and ribavirin (PEG-IFN/RBV) is the first listed.
NCT00747539 reports 4 study locations spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00747539 about?
NCT00747539 is a clinical study titled "Brain Deficits in HIV/HCV Coinfected People Before and After Anti-HCV Therapy". This study will evaluate the impact of standard hepatitis C virus treatment on brain deficits in people who are infected with both HIV and the hepatitis C virus.
What is the current status of trial NCT00747539?
This trial is currently completed. The enrollment target is 330 participants. The study started on 2008-07. Estimated completion is 2015-06.
What conditions does trial NCT00747539 study?
This clinical trial studies the following conditions: HIV, Hepatitis C, Infections.
What interventions are being tested in trial NCT00747539?
The interventions under investigation include: Pegylated interferon alfa and ribavirin (PEG-IFN/RBV) (DRUG).
Who is sponsoring clinical trial NCT00747539?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00747539 being conducted?
This trial has 4 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Transitional Housing and HIV Health
RECRUITING
-
Clinical Trial to Evaluate the Safety and Immunogenicity of a Priming Regimen of 426c.Mod.Core-C4b Followed by HxB2.WT.Core-C4b Boosts, Both Adjuvanted With 3M-052 AF + Alum, in Adult Participants Without HIV and in Overall Good Health
RECRUITING · Phase 1
-
Leukapheresis Procedures to Obtain Plasma and Lymphocytes for Research Studies on Antiretroviral Naive HIV-1 Research Participants
RECRUITING
-
Evaluating Gardasil HPV Vaccine Humoral and Cellular Immune Responses in People With and Without HIV
RECRUITING · Phase 2
-
Text Education About Cardiovascular Health and HIV (TEACH-HIV)
RECRUITING · NA
-
1MoreStep: An Intervention to Increase HIV Care Engagement and Reduce Intimate Partner Violence Among Black Women Living With HIV
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.